Clinical Trial Update: Study to Test the Safety and How Well Patients With Severe Hemophilia A Respond to Treatment With BAY 2599023 (DTX 201), a Drug Therapy That Delivers a Healthy Version of the Defective Factor VIII Gene Into the Nucleus of Liver Cells Using an Altered, Non-infectious Virus (AAV) as a "Shuttle" [Phase 1, Phase 2]

View source ↗

Summary

An early-phase clinical trial update evaluating BAY 2599023 (DTX 201), a gene therapy that delivers a functional factor VIII gene using an altered AAV shuttle, …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hemophilia

Drugs mentioned

• BAY 2599023 (DTX 201) (DTX 201)

Snippet

Sponsor: Bayer | Conditions: Hemophilia A | Phase 1, Phase 2 | Status: ACTIVE_NOT_RECRUITING